References
de Vries MK et al. (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66: 1252–1254
Maini RN et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563
Haibel H et al. (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66: 419–421
Baert F et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608
Pérez-Guijo VC et al. (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74: 254–258
Acknowledgements
The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J Sieper has declared that he is a consultant for, and has received speaker's bureau (honoraria) and grant/research support from, Abbott, Schering–Plough and Wyeth.
Rights and permissions
About this article
Cite this article
Sieper, J. Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?. Nat Rev Rheumatol 4, 398–399 (2008). https://doi.org/10.1038/ncprheum0846
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0846
- Springer Nature Limited